Free tool
FAERS Monitor: Epidiolex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210365 or its brand name (Epidiolex, Cannabidiol). Reports on generic versions are filed under their own applications.
Reports
24,103
Serious
14,267
59% of reports
Hospitalization
7,388
Death reported
1,929
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure6,169
- hospitalisation2,670
- off label use2,520
- product use in unapproved indication1,809
- diarrhoea1,776
- drug ineffective1,445
- death1,374
- somnolence1,340
- fatigue1,231
- product dose omission issue1,191
- weight decreased890
- weight increased845
- vomiting753
- decreased appetite735
- nausea678
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2014 | 3 |
| 2015 | 28 |
| 2016 | 35 |
| 2017 | 92 |
| 2018 | 232 |
| 2019 | 3,463 |
| 2020 | 3,556 |
| 2021 | 4,386 |
| 2022 | 3,787 |
| 2023 | 2,469 |
| 2024 | 2,045 |
| 2025 | 2,201 |
| 2026 | 1,805 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,030,056 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| seizureSignal | 6,169 | 49.2 | 48.1 | 277,095 |
| hospitalisationSignal | 2,670 | 15.4 | 14.9 | 35,610 |
| product use in unapproved indicationSignal | 1,809 | 6.4 | 6.1 | 8,290 |
| somnolenceSignal | 1,340 | 5.8 | 5.5 | 5,385 |
| product dose omission issueSignal | 1,191 | 3.5 | 3.4 | 2,195 |
| weight increasedSignal | 845 | 3.3 | 3.1 | 1,363 |
| weight decreasedSignal | 890 | 2.8 | 2.6 | 1,029 |
| decreased appetiteSignal | 735 | 2.8 | 2.6 | 834 |
| off label useSignal | 2,520 | 2.5 | 2.4 | 2,393 |
| diarrhoeaSignal | 1,776 | 2.4 | 2.3 | 1,498 |
| vomiting | 753 | 1.4 | 1.3 | 87 |
| death | 1,374 | 1.4 | 1.3 | 158 |
| fatigue | 1,231 | 1.4 | 1.3 | 133 |
| drug ineffective | 1,445 | 1.0 | 0.9 | 3 |
| nausea | 678 | 0.7 | 0.7 | 60 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.